Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma (MM) patients (PTS).

被引：0
|
作者：
Hussein, MA [1 ]
Bocock, K [1 ]
Bloom, T [1 ]
Finke, J [1 ]
Rybicki, L [1 ]
Scott, R [1 ]
Bukowski, RM [1 ]
机构：
[1] Cleveland Clin, Ctr Canc, Cleveland, OH 44106 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
444
引用
收藏
页码：108A / 109A
页数：2
相关论文
共 50 条
  • [41] High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action
    Adams, Homer, III
    Stevenaert, Frederik
    Krejcik, Jakub
    Van der Borght, Koen
    Casneuf, Tineke
    Smets, Tina
    Bald, Jaime
    Abraham, Yann
    Ceulemans, Hugo
    Vanhoof, Greet
    Ahmadi, Tahamtan
    Usmani, Saad Z.
    Plesner, Torben
    Lonial, Sagar
    van Kessel-Welmers, Berris
    Lokhorst, Henk M.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    Sasser, A. Kate
    BLOOD, 2016, 128 (22)
  • [42] Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency
    Badros, Ashraf Z.
    Vij, Ravi
    Martin, Thomas
    Zonder, Jeffrey A.
    Woo, Tina
    Wang, Zhengping
    Lee, Susan
    Wong, Alvin
    Niesvizky, Ruben
    BLOOD, 2009, 114 (22) : 1492 - 1492
  • [43] Treatment of all-trans retinoic acid (ATRA) plus tamoxifen and vitamin E in patients with advanced hepatocellular carcynoma.
    Clerici, C
    Toma, S
    Gentili, G
    Raffo, P
    Morelli, O
    Clementi, M
    Morelli, A
    HEPATOLOGY, 1998, 28 (04) : 760A - 760A
  • [44] Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes
    Stasi, R
    Brunetti, M
    Terzoli, E
    Amadori, S
    BLOOD, 2002, 99 (05) : 1578 - 1584
  • [45] Re-Evaluation of Risk Factors for Relapse in APL Patients Treated with All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) Frontline Chemotherapy
    Zhou, Y.
    Luthra, R.
    Ravandi, F.
    Kantarjian, H.
    Jorgensen, J. L.
    Bueso-Ramos, C.
    Medeiros, L. J.
    Konoplev, S.
    LABORATORY INVESTIGATION, 2012, 92 : 385A - 385A
  • [46] Re-Evaluation of Risk Factors for Relapse in APL Patients Treated with All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) Frontline Chemotherapy
    Zhou, Y.
    Luthra, R.
    Ravandi, F.
    Kantarjian, H.
    Jorgensen, J. L.
    Bueso-Ramos, C.
    Medeiros, L. J.
    Konoplev, S.
    MODERN PATHOLOGY, 2012, 25 : 385A - 385A
  • [47] Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial
    Koskela, K
    Pelliniemi, TT
    Pulkki, K
    Remes, K
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 749 - 754
  • [48] Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)
    Rifkin, Robert M.
    Chen, Clara
    Dhanda, Rahul
    Rembert, Debra
    Ba-Mancini, Abbie
    Ma, Esprit
    Zhu, Yanyan
    Dow, Edward
    Niculescu, Liviu
    BLOOD, 2013, 122 (21)
  • [49] CLINICAL AND PHARMACOKINETIC STUDIES OF ALL-TRANS-RETINOIC ACID IN PEDIATRIC-PATIENTS WITH CANCER
    ADAMSON, PC
    LEUKEMIA, 1994, 8 (11) : 1813 - 1816
  • [50] Oral high dose dexamethasone: clinical use in patients with multiple myeloma
    Saurel, Nathalie
    Calvez, Sophie
    Brasseur, Yvette
    Do, Bernard
    Berleur, Marie-Pierre
    PHARMACY WORLD & SCIENCE, 2009, 31 (01): : 62 - 62
12345